Neuraxis, INC (NRXS) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
11611 N. MERIDIAN ST CARMEL, IN 46032 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 3845 - Electromedical and Electrotherapeutic Apparatus (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 3,697 | 79 | |||
| Cash and cash equivalent | 3,697 | 79 | |||
| Receivables | 245 | 73 | |||
| Inventory, net of allowances, customer advances and progress billings | 44 | 21 | |||
| Inventory | 44 | 21 | |||
| Prepaid expense | |||||
| Other undisclosed current assets | 280 | 70 | |||
| Total current assets: | 4,266 | 243 | |||
| Noncurrent Assets | |||||
| Operating lease, right-of-use asset | 285 | 70 | |||
| Property, plant, and equipment, after accumulated depreciation, depletion, and amortization | 90 | 89 | |||
| Intangible asset, including goodwill, after accumulated amortization | 97 | 108 | |||
| Intangible asset, excluding goodwill, after accumulated amortization | 97 | 108 | |||
| Other noncurrent assets | |||||
| Other undisclosed noncurrent assets | 20 | ||||
| Total noncurrent assets: | 491 | 267 | |||
| TOTAL ASSETS: | 4,758 | 509 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,175 | 1,605 | |||
| Accounts payable | 597 | 1,204 | |||
| Accrued liabilities | 1,578 | 401 | |||
| Debt | 154 | 148 | |||
| Other liabilities | 49 | ||||
| Other undisclosed current liabilities | 104 | 83 | |||
| Total current liabilities: | 2,433 | 1,886 | |||
| Noncurrent Liabilities | |||||
| Liabilities, other than long-term debt | 256 | 27 | |||
| Other liabilities | |||||
| Operating lease, liability | 256 | 27 | |||
| Total noncurrent liabilities: | 256 | 27 | |||
| Total liabilities: | 2,690 | 1,913 | |||
| Equity | |||||
| Equity, attributable to parent | 2,068 | (1,403) | |||
| Preferred stock | 4 | ||||
| Common stock | 7 | 7 | |||
| Additional paid in capital | 58,856 | 47,148 | |||
| Accumulated deficit | (56,800) | (48,558) | |||
| Total equity: | 2,068 | (1,403) | |||
| TOTAL LIABILITIES AND EQUITY: | 4,758 | 509 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|
| Revenues | 2,686 | 2,460 | ||
| Cost of revenue (Cost of Product and Service Sold) | (362) | (303) | ||
| Gross profit: | 2,324 | 2,157 | ||
| Operating expenses | (9,481) | (8,821) | ||
| Operating loss: | (7,157) | (6,664) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (1,085) | (7,962) | ||
| Interest and debt expense | (3,650) | |||
| Net loss: | (8,242) | (18,276) | ||
| Other undisclosed net income attributable to parent | 3,650 | |||
| Net loss attributable to parent: | (8,242) | (14,627) | ||
| Preferred stock dividends and other adjustments | (211) | |||
| Net loss available to common stockholders, diluted: | (8,453) | (14,627) | ||
Comprehensive Income ($ in thousands)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|
| Net loss: | (8,242) | (18,276) | ||
| Comprehensive loss, net of tax, attributable to parent: | (8,242) | (18,276) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.